Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EPIZYME, INC.

(EPZM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société EPIZYME, INC.
09/15EPIZYME : Announces Data from TAZVERIK (Tazemetostat) Clinical Programs to be Pr..
AQ
09/14EPIZYME : Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be P..
BU
08/23EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
08/20EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
08/16EPIZYME : FIFTH AMENDMENT TO LEASE (Form 8-K)
PU
08/16EPIZYME, INC. : Entry into a Material Definitive Agreement, Financial Statements..
AQ
08/09EPIZYME : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/09EPIZYME : and HUTCHMED Announce Strategic Collaboration to Develop and Commercia..
AQ
08/09EPIZYME, INC. : Entry into a Material Definitive Agreement, Results of Operation..
AQ
08/09EPIZYME : Q2 Earnings Snapshot
AQ
08/09EPIZYME : Announces CEO Succession
BU
08/09EPIZYME : Reports Second Quarter 2021 Financial Results and Provides Business Up..
BU
08/03EPIZYME : Announces Date of Second Quarter 2021 Financial Results
BU
06/28EPIZYME, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/24EISAI : ANTICANCER AGENT 'TAZVERIK TABLETS 200mg' APPROVED IN JAPAN FOR EZH2 GEN..
AQ
06/16EPIZYME, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/16EPIZYME : Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed o..
BU
05/25EPIZYME : to Participate in Jefferies Virtual Healthcare Conference
BU
05/12EPIZYME : Announces Preclinical and Clinical Data to be Presented in Oral and Po..
BU
05/06EPIZYME : Management's Discussion and Analysis of Financial Condition and Result..
AQ
05/06EPIZYME, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
05/06EPIZYME : Q1 Earnings Snapshot
AQ
05/06EPIZYME : Provides Business Update and Reports First Quarter 2021 Financial Resu..
BU
04/29EPIZYME : Announces Date of First Quarter 2021 Financial Results
BU
03/09EPIZYME : Barclays Conference Presentation - March 2021
PU
03/03EPIZYME : Cowen Conference Presentation - March 2021
PU
03/02EPIZYME : Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline..
BU
02/24EPIZYME : Provides Business Update and Reports Fourth Quarter and Full Year 2020..
AQ
02/24EPIZYME : to Host Strategic Vision Call on March 2, 2021
BU
02/23EPIZYME : Results of Operations and Financial Condition, Financial Statements an..
AQ
02/23EPIZYME : Management's Discussion and Analysis of Financial Condition and Result..
AQ
02/23EPIZYME, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
02/23EPIZYME : 4Q Earnings Snapshot
AQ
02/23EPIZYME : CORRECTING and REPLACING Epizyme Provides Business Update and Reports ..
BU
02/16EPIZYME : Announces Date of Fourth Quarter and Full Year 2020 Financial Results ..
BU
2020EPIZYME, INC. : Termination of a Material Definitive Agreement (form 8-K)
AQ
2020EPIZYME : to Participate in Jefferies Virtual London Healthcare Conference
BU
2020EPIZYME : Reports Business Progress and Third Quarter 2020 Financial Results
AQ
2020EPIZYME : Announces Expanded Loan Facility with Pharmakon Advisors for Additiona..
AQ
2020EPIZYME : 3Q Earnings Snapshot
AQ
2020EPIZYME, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
2020EPIZYME : Reports Business Progress and Third Quarter 2020 Financial Results
BU
2020EPIZYME : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2020EPIZYME : Announces Expanded Loan Facility with Pharmakon Advisors for Additiona..
BU
2020EPIZYME : Announces Date of Third Quarter 2020 Financial Results
AQ
2020EPIZYME : Announces Date of Third Quarter 2020 Financial Results
BU
2020EPIZYME : Announces Two Lancet Oncology Publications on TAZVERIK Phase 2 Data in..
AQ
2020EPIZYME : Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat)..
BU
2020EPIZYME : to Participate in Morgan Stanley 18th Annual Global Healthcare Confere..
BU
2020EPIZYME : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2020EPIZYME, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
2020EPIZYME : 2Q Earnings Snapshot
AQ
2020EPIZYME : Reports Business Progress and Second Quarter 2020 Financial Results
BU
2020EPIZYME : Announces Date of Second Quarter 2020 Financial Results and Participat..
BU
2020EISAI : Submits marketing authorization application in japan for anticancer agen..
AQ
2020EPIZYME : Announces U.S. FDA Accelerated Approval of TAZVERIK for Relapsed/Refra..
AQ
2020EPIZYME :  Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (t..
BU
2020EPIZYME, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2020EPIZYME : to Present Data from Tazemetostat Clinical Program during the 2020 ASC..
BU
2020EPIZYME, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
2020EPIZYME : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2020EPIZYME : 1Q Earnings Snapshot
AQ
2020EPIZYME : Reports Business Progress and First Quarter 2020 Financial Results
BU
2020EPIZYME : Announces Date of First Quarter 2020 Financial Results
BU
2020EPIZYME : Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
AQ
2020EPIZYME : Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
BU
2020EPIZYME : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2020EPIZYME : Corporate Presentation, Feb. 2020
PU
2020EPIZYME : 4Q Earnings Snapshot
AQ
2020EPIZYME, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
2020EPIZYME : Provides Business Update and Reports Fourth Quarter and Full Year 2019..
BU
2020EPIZYME : Announces Date of Fourth Quarter and Full Year 2019 Results and Presen..
BU
2020EPIZYME : Announces FDA Acceptance of New Drug Application for Filing with Prior..
AQ
2020EPIZYME : Announces FDA Acceptance of New Drug Application for Filing with Prior..
BU
2020EPIZYME : Statement of changes in beneficial ownership of securities
PU
1  2  3  4Next
Upcoming event on EPIZYME, INC.